Dr Reddy's Lab launches generic version of Quelicin in US markets
Dr Reddy’s Laboratories informed the exchanges after trading hours on Thursday that it has launched Succinylcholine Chloride injection USP, 200 mg/10 ml (20 mg/ml), multiple-dose vials in the US markets.
The said drug, which is approved by the US Food & Drug Administration (USFDA), is the therapeutic equivalent generic version of Quelicin (Succinylcholine Chloride) injection, 20 mg/ml.
According to MAT data from IMS Health, in the most-recent twelve-month ending in September 2020, the Quelicin brand and the generic market had US sales of around US$ 74.8 million
The drug is indicated as an adjunct to general anaesthesia to provide skeletal muscle relaxation during surgery or mechanical ventilation.
At 1.30 pm on Friday, the stock of Dr Reddy’s Laboratories was trading at Rs 4,855 per share, up by 0.59 per cent or Rs 28.25 per share on BSE, against a 0.13 per cent decline in the benchmark index. The 52-week high is recorded at Rs 5,514.65 and the 52-week low is Rs 2,497.60 on BSE.